Generic Aptivus Availability

Aptivus is a brand name of tipranavir, approved by the FDA in the following formulation(s):

APTIVUS (tipranavir - capsule;oral)

APTIVUS (tipranavir - solution;oral)

Has a generic version of Aptivus been approved?

No. There is currently no therapeutically equivalent version of Aptivus available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aptivus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pyranone compounds useful to treat retroviral infections
    Patent 5,852,195
    Issued: December 22, 1998
    Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
    Assignee(s): Pharmacia & Upjohn Company
    The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl›b!pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1##
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Drug substance
    • December 22, 2019
      ✓ 
      Pediatric exclusivity
  • Method for improving the pharmacokinetics of tipranavir
    Patent 6,147,095
    Issued: November 14, 2000
    Inventor(s): Ferry; James J. & Baldwin; John R. & Borin; Marie T.
    Assignee(s): Pharmacia & Upjohn Company
    The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:
    • October 29, 2019
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
    • April 29, 2020
      ✓ 
      Pediatric exclusivity
  • Compounds useful to treat retroviral infections
    Patent 6,169,181
    Issued: January 2, 2001
    Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
    Assignee(s): Pharmacia & Upjohn Company
    The present invention relates to compounds of formula I and II which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. ##STR1## wherein R.sub.10 and R.sub.20 taken together are: ##STR2##
    Patent expiration dates:
    • May 6, 2014
      ✓ 
      Drug substance
    • November 6, 2014
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
    Patent 6,231,887
    Issued: May 15, 2001
    Inventor(s): Gao; Ping & Morozowich; Walter
    Assignee(s): Pharmacia & Upjohn Company
    The present invention provides a novel pharmaceutical composition based on the use of a particular amount of basic amine which comprises a pyranone compound as a pharmaceutically active agent, a basic amine in an amount of from about 0.1% to about 10% by weight of the total composition, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. In addition, the composition may further comprises one or more pharmaceutically acceptable oils. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic pyranone compounds.
    Patent expiration dates:
    • July 27, 2018
      ✓ 
      Drug product
    • January 27, 2019
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)